Low-dose continuous 5-fluorouracil infusion stimulates VEGF-A-mediated angiogenesis

Acta Oncologica

Volumn 48, Issue 3, 2009, Pages 418-425

  Albertsson, Per ^a,b   Lennerns, Bo ^a   Norrby, Klas ^a  

^a UNIVERSITY OF GOTHENBURG   (Sweden)

^b Rigshospitalet   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENIC FACTOR; ANTINEOPLASTIC AGENT; FLUOROURACIL; VASCULOTROPIN A; ANTINEOPLASTIC ANTIMETABOLITE; VASCULAR ENDOTHELIAL GROWTH FACTOR A, RAT;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CANCER PATIENT; CONTINUOUS INFUSION; CONTROLLED STUDY; DRUG EFFECT; DRUG INFUSION; DRUG RESPONSE; IMPLANT; LOW DRUG DOSE; MALE; MESENTERY; MORPHOMETRICS; NONHUMAN; OSMOTIC PUMP; PRIORITY JOURNAL; RAT; SPRAGUE DAWLEY RAT; TUMOR; ANIMAL; CELL PROLIFERATION; CYTOLOGY; DOSE RESPONSE; SUBCUTANEOUS DRUG ADMINISTRATION; VASCULAR ENDOTHELIUM; VASCULARIZATION; WEIGHT GAIN;

ANIMALS; ANTIMETABOLITES, ANTINEOPLASTIC; CELL PROLIFERATION; DOSE-RESPONSE RELATIONSHIP, DRUG; ENDOTHELIUM, VASCULAR; FLUOROURACIL; INFUSIONS, SUBCUTANEOUS; MALE; MESENTERY; NEOVASCULARIZATION, PHYSIOLOGIC; RATS; RATS, SPRAGUE-DAWLEY; VASCULAR ENDOTHELIAL GROWTH FACTOR A; WEIGHT GAIN;

EID: 65349163383     PISSN: 0284186X     EISSN: 1651226X     Source Type: Journal    
DOI: 10.1080/02841860802409512     Document Type: Article

References (36)

1. Longley DB, Harkin DP, Johnston PG. 5-fluorouracil: Mechanisms of action and clinical strategies. Nat Rev Cancer 2003;/3:/330-8.
2. Lokich J, Anderson N. Dose intensity for bolus versus infusion chemotherapy administration: Review of the literature for 27 anti-neoplastic agents. Ann Oncol 1997;/8:/15-25.
3. Hanahan D, Bergers G, Bergsland E. Less is more, regularly: Metronomic dosing of cytotoxic drugs can target tumor angiogenesis in mice. J Clin Invest 2000;/105:/1045-7.
4. Browder T, Butterfield CE, Kraling BM, Shi B, Marshall B, O'Reilly MS, et al. Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer. Cancer Res 2000;/60:/1878-86.
5. Albertsson P, Lennernas B, Norrby K. On metronomic chemotherapy: Modulation of angiogenesis mediated by VEGF-A. Acta Oncol 2006;/45:/144-55.
6. Drevs J, Fakler J, Eisele S, Medinger M, Bing G, Esser N et al. Antiangiogenic potency of various chemotherapeutic drugs for metronomic chemotherapy. Anticancer Res 2004;/ 24:/1759-63.
7. Norrby K. In vivo models of angiogenesis. J Cell Mol Med 2006;/10:/588-612.
8. Lennernas B, Albertsson P, Lennernas H, Norrby K. Chemotherapy and antiangiogenesis-drug-specific, dose-related effects. Acta Oncol 2003;/42:/294-303.
9. Albertsson P, Lennernas B, Norrby K. Dose effects of continuous vinblastine chemotherapy on mammalian angiogenesis mediated by VEGF-A. Acta Oncol 2008;/47:/ 293-300.
10. Lennernas B, Albertsson P, Damber JE, Norrby K. Antiangiogenic effect of metronomic paclitaxel treatment in prostate cancer and non-tumor tissue in the same animals: A quantitative study. Apmis 2004;/112:/201-9.
11. Albertsson P, Lennernas B, Norrby K. Chemotherapy and antiangiogenesis: Drug-specific effects on microvessel sprouting. Apmis 2003;/111:/995-1003. (Pubitemid 37521892)
12. United Kingdom Co-ordinating Committee on Cancer Research (UKCCCR) Guidelines for the welfare of animals in experimental neoplasia. 2nd ed. Br J Cancer 1998;77: 1-10.
13. Freireich EJ, Gehan EA, Rall DP, Schmidt LH, Skipper HE. Quantitative comparison of toxicity of anticancer agents in mouse, rat, hamster, dog, monkey, and man. Cancer Chemother Rep 1966;/50:/219-44.
14. Norrby K. Microvascular density in terms of number and length of microvessel segments per unit tissue volume in mammalian angiogenesis. Microvasc Res 1998;/55:/43-53.
15. Maulik N. Redox signaling of angiogenesis. Antioxid Redox Signal 2002;/4:/805-15.
16. Stoeltzing O, Liu W, Reinmuth N, Fan F, Parry GC, Parikh AA, et al. Inhibition of integrin alpha5beta1 function with a small peptide (ATN-161) plus continuous 5-FU infusion reduces colorectal liver metastases and improves survival in mice. Int J Cancer 2003;/104:/496-503.
17. Basaki Y, Chikahisa L, Aoyagi K, Miyadera K, Yonekura K, Hashimoto A, et al. gamma-Hydroxybutyric acid and 5-fluorouracil, metabolites of UFT, inhibit the angiogenesis induced by vascular endothelial growth factor. Angiogenesis 2001;/4:/163-73.
18. Steiner R. Angiostatic activity of anticancer agents in the chick embryo chorioallantoic membrane (CHE-CAM) assay. Exs 1992;/61:/449-54.
19. Norrby K. Drug testing with angiogenesis models. Expert Opin Drug Discov 2008;/3:/1-17.
20. Folkman J. Angiogenesis: An organizing principle for drug discovery? Nat Rev Drug Discov 2007;/6:/273-86. (Pubitemid 46505878)
21. Brown NS, Bicknell R. Thymidine phosphorylase, 2-deoxy-D-ribose and angiogenesis. Biochem J 1998;/334:/1-8.
22. Brown NS, Jones A, Fujiyama C, Harris AL, Bicknell R. Thymidine phosphorylase induces carcinoma cell oxidative stress and promotes secretion of angiogenic factors. Cancer Res 2000;/60:/6298-302.
23. Focher F, Spadari S. Thymidine phosphorylase: A two-face Janus in anticancer chemotherapy. Curr Cancer Drug Targets 2001;/1:/141-53.
24. Toi M, Atiqur Rahman M, Bando H, Chow LW. Thymidine phosphorylase (platelet-derived endothelial-cell growth factor) in cancer biology and treatment. Lancet Oncol 2005;/6:/ 158-66.
25. Hotchkiss KA, Ashton AW, Klein RS, Lenzi ML, Zhu GH, Schwartz EL. Mechanisms by which tumor cells and monocytes expressing the angiogenic factor thymidine phosphorylase mediate human endothelial cell migration. Cancer Res 2003;/63:/527-33.
26. Ishikawa F, Miyazono K, Hellman U, Drexler H, Wernstedt C, Hagiwara K, et al. Identification of angiogenic activity and the cloning and expression of platelet-derived endothelial cell growth factor. Nature 1989;/338(6216):/557-62.
27. Liekens S, Bilsen F, De Clercq E, Priego EM, Camarasa MJ, Perez-Perez MJ, et al. Anti-angiogenic activity of a novel multi-substrate analogue inhibitor of thymidine phosphorylase. FEBS Lett 2002;/510:/83-8.
28. Seeliger H, Guba M, Koehl GE, Doenecke A, Steinbauer M, Bruns CJ, et al. Blockage of 2-deoxy-D-ribose-induced angiogenesis with rapamycin counteracts a thymidine phosphorylase-based escape mechanism available for colon cancer under 5-fluorouracil therapy. Clin Cancer Res 2004;/ 10:/1843-52.
29. Schirner M, Hoffmann J, Menrad A, Schneider MR. Antiangiogenic chemotherapeutic agents: Characterization in comparison to their tumor growth inhibition in human renal cell carcinoma models. Clin Cancer Res 1998;/4:/ 1331-6.
30. Schwartz PM, Dunigan JM, Marsh JC, Handschumacher RE. Allopurinol modification of the toxicity and antitumor activity of 5-fluorouracil. Cancer Res 1980;/40:/1885-9.
31. Howell SB, Wung WE, Taetle R, Hussain F, Romine JS. Modulation of 5-fluorouracil toxicity by allopurinol in man. Cancer 1981;/48:/1281-9.
32. Kinhult S, Albertsson M, Eskilsson J, Cwikiel M. Effects of probucol on endothelial damage by 5-fluorouracil. Acta Oncol 2003;/42:/304-8.
33. Alexandre J, Nicco C, Chereau C, Laurent A, Weill B, Goldwasser F, et al. Improvement of the therapeutic index of anticancer drugs by the superoxide dismutase mimic mangafodipir. J Natl Cancer Inst 2006;/98:/236-44.
34. Efficacy of intravenous continuous infusion of fluorouracil compared with bolus administration in advanced colorectal cancer. Meta-analysis Group In Cancer. J Clin Oncol 1998; 16:301-8.
35. Glimelius B, Sorbye H, Balteskard L, Bystrom P, Pfeiffer P, Tveit K, et al. A randomized phase III multicenter trial comparing irinotecan in combination with the Nordic bolus 5-FU and folinic acid schedule or the bolus/infused de Gramont schedule (Lv5FU2) in patients with metastatic colorectal cancer. Ann Oncol 2008;/19:/909-14.
36. Fuchs CS, Marshall J, Mitchell E, Wierzbicki R, Ganju V, Jeffery M, et al. Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: Results from the BICC-C Study. J Clin Oncol 2007;/25:/4779-86.